7-Dec-2025 ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients University of Texas M. D. Anderson Cancer Center Reports and Proceedings
7-Dec-2025 ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma University of Texas M. D. Anderson Cancer Center Reports and Proceedings
7-Dec-2025 Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes American Society of Hematology Reports and Proceedings
7-Dec-2025 New findings support a chemo-free approach for treating Ph+ ALL American Society of Hematology Reports and Proceedings
7-Dec-2025 Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL American Society of Hematology Reports and Proceedings
6-Dec-2025 University of Cincinnati experts present research at annual hematology event University of Cincinnati Meeting Announcement
6-Dec-2025 ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers University of Texas M. D. Anderson Cancer Center Reports and Proceedings
6-Dec-2025 ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma University of Texas M. D. Anderson Cancer Center Reports and Proceedings
6-Dec-2025 ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial University of Miami Miller School of Medicine Reports and Proceedings
6-Dec-2025 ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer University of Miami Miller School of Medicine Reports and Proceedings